Rapid Therapeutic Antibody Development Using Fully Human Antibody Mouse
Therapeutic antibodies have been proven to be remarkably effective for immunotherapies. Most human antibodies were discovered through conventional antibody discovery process, which can be divided into a cascade of stages, including target selection and validation, screening preparation, hits generation, leads selection, lead optimization, and clinical candidate selection. To revolutionize the current antibody discovery process, Biocytogen has developed a fully human antibody mouse (RenMab™ Mouse), whose entire variable regions are replaced by human Ig heavy chain and κ light chain through chromosome engineering. RenMab™ Mouse provides an efficient therapeutic antibody discovery platform for fully human antibody generation, characterization, and rapid in vivo efficacy screening. Key highlights of RenMab™ Mouse are as follows.
- Entire mouse variable regions were replaced in situ with the intact human genome DNA for the complete human & mouse regulatory elements. Therefore, gene regulation in RenMab™ Mouse is highly consistent with that in human.
- Mouse constant region is retained for normal immune cell population, development and maturation. Immune system of RenMab™ Mouse has been shown to be almost identical to that of wild type mice.
- Mouse V, D, J gene segments were replaced in situ by human V, D, J segments through chromosome engineering. V(D)J recombination results in a highly diverse repertoire of antibodies, as well as significantly improved success rate of antibody drug discovery.
In conclusion, Biocytogen’s RenMab™ Mouse has been validated to be a fully human antibody mouse, exhibiting superior immune cell profile and rapid immune response. With RenMab™ Mouse , a world-leading proprietary gene editing technology and hundreds of humanized mouse models, Biocytogen is poised to provide one-stop solution from target validation to IND application for antibody therapeutics.